CyberIntel ⬡ News
★ Saved ◆ Cyber Reads
← Back ◬ AI & Machine Learning Jun 18, 2026

TxBench-PP: Analyzing AI Agent Performance on Small-Molecule Preclinical Pharmacology

arXiv AI Archived Jun 18, 2026 ✓ Full text saved

arXiv:2606.19245v1 Announce Type: new Abstract: Artificial intelligence (AI) agents promise to accelerate drug discovery by compressing interpretation and decision-making loops, but practical deployment requires trusted evaluation on realistic program decisions. We introduce TherapeuticsBench Preclinical Pharmacology (TxBench-PP), a verifiable benchmark for small-molecule preclinical pharmacology and the first focused slice of a broader TherapeuticsBench effort across drug-discovery stages and t

Full text archived locally
✦ AI Summary · Claude Sonnet


    Computer Science > Artificial Intelligence [Submitted on 17 Jun 2026] TxBench-PP: Analyzing AI Agent Performance on Small-Molecule Preclinical Pharmacology Hannah Le, Ramesh Ramasamy, Alex Urrutia, Mahsa Yazdani, Tim Proctor, Kenny Workman Artificial intelligence (AI) agents promise to accelerate drug discovery by compressing interpretation and decision-making loops, but practical deployment requires trusted evaluation on realistic program decisions. We introduce TherapeuticsBench Preclinical Pharmacology (TxBench-PP), a verifiable benchmark for small-molecule preclinical pharmacology and the first focused slice of a broader TherapeuticsBench effort across drug-discovery stages and therapeutic modalities. TxBench-PP tests whether agents can recover accurate conclusions from real-world assay data rather than memorized facts from literature. The benchmark contains 100 evaluations indexed by program stage, assay type, and task structure, spanning mechanism-of-action (MoA) and pharmacodynamic (PD) reasoning, compound-target engagement, causal target validation, developability and safety, and translational efficacy. Agents receive realistic workflow snapshots, inspect files in a coding environment, and return structured answers graded deterministically. Across 16 model-harness configurations, comprising 11 models and 4,800 trajectories, no system reliably recovered preclinical pharmacology decisions. The strongest configuration, Claude Opus 4.8 / Pi, passed 59.3\% of endpoint attempts (178/300; 95\% CI, 51.1-67.6), followed by GPT-5.5 / Pi at 55.3\% (166/300; 47.0-63.6). Subjects: Artificial Intelligence (cs.AI); Machine Learning (cs.LG) Cite as: arXiv:2606.19245 [cs.AI]   (or arXiv:2606.19245v1 [cs.AI] for this version)   https://doi.org/10.48550/arXiv.2606.19245 Focus to learn more Submission history From: Kenny Workman B [view email] [v1] Wed, 17 Jun 2026 16:23:45 UTC (264 KB) Access Paper: HTML (experimental) view license Current browse context: cs.AI < prev   |   next > new | recent | 2026-06 Change to browse by: cs cs.LG References & Citations NASA ADS Google Scholar Semantic Scholar Export BibTeX Citation Bookmark Bibliographic Tools Bibliographic and Citation Tools Bibliographic Explorer Toggle Bibliographic Explorer (What is the Explorer?) Connected Papers Toggle Connected Papers (What is Connected Papers?) Litmaps Toggle Litmaps (What is Litmaps?) scite.ai Toggle scite Smart Citations (What are Smart Citations?) Code, Data, Media Demos Related Papers About arXivLabs Which authors of this paper are endorsers? | Disable MathJax (What is MathJax?)
    💬 Team Notes
    Article Info
    Source
    arXiv AI
    Category
    ◬ AI & Machine Learning
    Published
    Jun 18, 2026
    Archived
    Jun 18, 2026
    Full Text
    ✓ Saved locally
    Open Original ↗